Safety, tolerability, PK [pharmacokinetics] and PD [pharmacodynamics] of LY2405319 after multiple subcutaneous injections in subjects with type 2 diabetes
Phase of Trial: Phase I
Latest Information Update: 10 Sep 2010
At a glance
- Drugs LY 2405319 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 10 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Sep 2008 Status changed from not yet recruiting to recruiting.
- 12 Aug 2008 The planned initiation date for this trial is now August 2008 accoring to clincialtrials.gov record.